Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vaccitech plc
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
September 13, 2023
From
Vaccitech plc
Via
GlobeNewswire
Tickers
VACC
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
August 10, 2023
From
Vaccitech plc
Via
GlobeNewswire
Tickers
VACC
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
June 21, 2023
From
Vaccitech plc
Via
GlobeNewswire
Tickers
VACC
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
June 12, 2023
From
Vaccitech plc
Via
GlobeNewswire
Tickers
VACC
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
April 17, 2023
From
Vaccitech plc
Via
GlobeNewswire
Tickers
VACC
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
March 28, 2023
From
Vaccitech plc
Via
GlobeNewswire
Tickers
VACC
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
March 24, 2023
From
Vaccitech plc
Via
GlobeNewswire
Tickers
VACC
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
March 20, 2023
From
Vaccitech plc
Via
GlobeNewswire
Tickers
VACC
Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
January 30, 2023
From
Vaccitech plc
Via
GlobeNewswire
Tickers
VACC
Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 10, 2022
From
Vaccitech plc
Via
GlobeNewswire
Tickers
VACC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.